1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Mar 2024
Admin
News Article

Veeda Acquires a European CRO, Heads

Veeda Clinical Research acquires European CRO, Heads to expand global reach & capabilities

Overview

Veeda Clinical Research a full-service contract research organization (CRO) has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.

About Heads

Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region.
Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.

Acquisition Benefits: for Heads

The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets.
India's diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases.

Acquisition Benefits: for Veeda

With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific.
Veeda’s ever-growing relationship with large biopharma companies and access to KOL’s across multiple countries will accelerate execution of global clinical trials in both the western and eastern populations.
In recent years, Veeda has added expertise in the late stage clinical and global trials for large molecules.
High quality and efficient clinical trial execution remains the top priority for the clients of the combined entity.

Words from CEO: Veeda Clinical Research

Dr. Mahesh Bhalgat, group- CEO, Veeda Clinical Research, said, “With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the oncology research. This equips Veeda to build long and enduring site relationships across geographies.

"There is a very strong cultural fit between Heads and Veeda," said Dr. George Kouvatseas, partner, Heads. Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, an uncompromising focus on quality, and a belief that our strength is in our people and the way in which they work together.

Responsibilities Post Acquisition

During the integration phase, Heads will continue to offer uninterrupted support to client programmes.
The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programmes.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!